Michael Demurjian serves as Chairman and CEO of Aspargo Labs, which he co-founded in 2019. He brings extensive experience across finance, manufacturing, sales & marketing, logistics, and general management. He has experience in taking companies public, raising funds in public and private markets with both retail and institutional investors. 

Prior to Aspargo Labs, Mr. Demurjian served as COO, CFO and member of the Board of Directors of Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. At Tyme, Mr. Demurjian was instrumental in raising over 50 million dollars and obtaining a public listing on NASDAQ. He also served as CEO of Luminant Biosciences, an oncology research company studying metabolic pathways to destroying cancer cells.

Throughout his career, Mr. Demurjian has successfully completed strategic transactions with G.E., Stryker, Black & Decker Corp., and Crane Cams. Mr. Demurjian currently sits on the Board of Directors of the Susan G. Komen Foundation, NYU and has served in the past on the Board of Directors of Luminant Bio., Mikronite Tech & KCC.